People on the Move: Dr. Gallia G. Levy Departs Spark Therapeutics to Join Kite as Global Head of Clinical Development
Dr. Gallia G. Levy departs Spark Therapeutics to join Kite, a Gilead company, as Global Head of Clinical Development. Dr. Levy’s move follows a series of leadership changes at Spark and marks a significant addition to Kite’s leadership team.
A month after CEO Ron Philip concluded his seven-year tenure at Spark Therapeutics to head to Orbital Therapeutics, Dr. Gallia Levy, MD, PhD, the company's Chief Medical Officer and Product Strategy Officer, has decided to join Kite as the Global Head of Clinical Development. Kite is a Gilead Company after Gilead acquired Kite in 2017 for $11.9 Billion.
Dr. Levy, who joined Spark in 2020, previously served as Vice President and Global Head of the Rare Blood Disorders franchise at Genentech, a Roche Company. In that role, she launched groundbreaking therapies, including HEMLIBRA® for hemophilia A.
Before her time at Spark, Dr. Levy was a key figure at Genentech, overseeing the clinical development of treatments for rare blood disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Her contributions significantly advanced the evolution of gene therapy within the Roche Group.
Dr. Levy earned her M.D. and Ph.D. in Molecular and Cellular Biology from the University of Michigan. She is board-certified in hematology and completed her residency in internal medicine at Stanford University, followed by a fellowship in hematology and oncology at UCSF. Additionally, she holds a master's degree from the University of Paris and a bachelor's degree from UC Berkeley.
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more CAR-T cell therapy patients than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production, and commercial product manufacturing.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, intending to create a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017.
